Aspen China is set to become a significant contributor to the Group performance with a product range comprising the recently acquired Thrombosis and Anaesthetic Brands as well as some smaller global brands.
Contribution to Group revenue
Revenue contribution - by therapeutic category
- China made up 37% of the total Asian pharmaceutical sector with an estimated value of USD80 billion as at 30 December 2016.
- Over the same period, the China pharmaceutical sector grew 7,9% in local currency, mostly driven by the 8,4% growth in prescription medication usage in hospitals.
Source: June 2017 IMS
Number of products launched:
Number of product recalls:
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:
0 – 2 years
3 – 5 years
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’million||2018||2017 (CER)||% change|
|Total||2 480||1 748||42|
|Commercial Pharmaceuticals||2 415||1 748||38|
|Anaesthetics||1 779||1 435||24|
|High Potency & Cytotoxics||20||47||(57)|